Managing Editor
@ShahidNShah
@ShahidNShah
AI and Decentralized Trials: A New Era in Drug Development
The decentralized clinical trial (DCT) model has been around for almost fifteen years, with Pfizer pioneering the first fully decentralized study in 2011, and adoption accelerating significantly following the onset of the COVID-19 pandemic in 2020. The clinical research landscape is currently undergoing a profound transformation, driven by the increasing employment of decentralized clinical trials. Traditional clinical trial models, which rely heavily on centralized study sites and in-person participation, have long been hindered by geographic, logistical, and financial barriers. These challenges have slowed patient recruitment and participation, limited trial diversity, and delayed access to life-saving treatments.The pandemic showed us that DCTs can change this dynamic, leveraging digital health technologies to bring trials directly to participants.
Medigy Insights
DCTs represent a fundamental shift in how clinical trials are conducted. Unlike traditional trials that require frequent in-person visits to designated research sites, DCTs utilize a combination of telemedicine, home-based diagnostics, wearable devices, and remote monitoring platforms. This approach minimizes patient burden while ensuring continuous data collection and trial oversight.
Continue reading at healthcareittoday.com
Make faster decisions with community advice
Next Article
-
Healthcare AI: What It Can Do And Where It's Heading
Hospitals are already deploying AI to improve patient outcomes. One standout example is Kansas City’s Saint Luke’s Health System. After implementing Epic's Early Detection of Sepsis system, they …
